ZNF674

Summary

ZNF674 (zinc finger protein 674, HGNC:17625) is a protein-coding gene on chromosome Xp11.3, encoding Zinc finger protein 674 (Q2M3X9). May be involved in transcriptional regulation.

This gene encodes a zinc finger protein with an N-terminal Kruppel-associated box-containing (KRAB) domain and 11 Kruppel-type C2H2 zinc finger domains. Like other zinc finger proteins, this gene may function as a transcription factor. This gene resides on an area of chromosome X that has been implicated in nonsyndromic X-linked cognitive disabilities. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 641339 — RefSeq curated summary.

At a glance

• Gene–disease (curated): X-linked intellectual disability (Disputed, ClinGen) — +1 more curated relationship
• Clinical variants (ClinVar): 97 total — 1 pathogenic
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001190417

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17625
Approved symbol	ZNF674
Name	zinc finger protein 674
Location	Xp11.3
Locus type	gene with protein product
Status	Approved
Aliases	ZNF673B
Ensembl gene	ENSG00000251192
Ensembl biotype	protein_coding
OMIM	300573
Entrez	641339

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 5 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000414387, ENST00000453909, ENST00000518708, ENST00000518795, ENST00000521626, ENST00000522017, ENST00000523374, ENST00000683375, ENST00000878263

RefSeq mRNA: 3 — MANE Select: NM_001190417 NM_001039891, NM_001146291, NM_001190417

CCDS: CCDS48099, CCDS55406, CCDS94605

Canonical transcript exons

ENST00000683375 — 6 exons

Exon	Start	End
ENSE00002278937	46544501	46544611
ENSE00003478176	46528783	46528909
ENSE00003479639	46528350	46528445
ENSE00003622372	46542073	46542116
ENSE00003918413	46497725	46501335
ENSE00003919673	46545371	46545421

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 80.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.4725 / max 100.7890, expressed in 1384 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199062	2.8790	1337
199060	0.2364	81
199061	0.2139	65
199059	0.1433	54

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.92	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.60	gold quality
cortical plate	UBERON:0005343	77.94	gold quality
calcaneal tendon	UBERON:0003701	74.18	gold quality
ganglionic eminence	UBERON:0004023	74.10	gold quality
colonic epithelium	UBERON:0000397	73.78	gold quality
ventricular zone	UBERON:0003053	73.70	gold quality
stromal cell of endometrium	CL:0002255	73.21	gold quality
hindlimb stylopod muscle	UBERON:0004252	72.02	gold quality
adrenal tissue	UBERON:0018303	71.66	gold quality
islet of Langerhans	UBERON:0000006	71.12	gold quality
monocyte	CL:0000576	71.09	gold quality
endometrium epithelium	UBERON:0004811	71.01	gold quality
mononuclear cell	CL:0000842	70.90	gold quality
leukocyte	CL:0000738	70.83	gold quality
gall bladder	UBERON:0002110	70.17	gold quality
gastrocnemius	UBERON:0001388	68.94	gold quality
muscle of leg	UBERON:0001383	68.91	gold quality
Brodmann (1909) area 10	UBERON:0013541	68.33	gold quality
body of uterus	UBERON:0009853	67.67	gold quality
smooth muscle tissue	UBERON:0001135	67.63	gold quality
left ovary	UBERON:0002119	67.63	gold quality
right ovary	UBERON:0002118	67.61	gold quality
right lobe of liver	UBERON:0001114	67.59	gold quality
prefrontal cortex	UBERON:0000451	67.51	gold quality
rectum	UBERON:0001052	67.50	gold quality
left adrenal gland	UBERON:0001234	67.21	gold quality
descending thoracic aorta	UBERON:0002345	67.15	gold quality
cerebellar cortex	UBERON:0002129	67.14	gold quality
cerebellar hemisphere	UBERON:0002245	67.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.99

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

93 targeting ZNF674, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-493-5P	99.96	72.47	2382
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-6780A-5P	99.88	66.69	2776

Functional genomics

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 2)

• Identification of ZNF674 as the third X-linked mental retardation gene in this cluster may indicate a common role for these zinc-finger genes that is crucial to human cognitive functioning. (PMID:16385466)
• These findings question the responsibility of ZNF674 deletions in intellectual disability (ID) associated with X-linked retinal dystrophy. (PMID:22126752)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp78	ENSMUSG00000055150
rattus_norvegicus		ENSRNOG00000083797
drosophila_melanogaster	CG2712	FBGN0024975
drosophila_melanogaster	Phs	FBGN0036522
drosophila_melanogaster	CG3281	FBGN0260741

Paralogs (62): ZNF582 (ENSG00000018869), ZNF264 (ENSG00000083844), ZNF343 (ENSG00000088876), ZNF684 (ENSG00000117010), ZNF133 (ENSG00000125846), ZNF557 (ENSG00000130544), ZNF337 (ENSG00000130684), ZNF20 (ENSG00000132010), ZFP37 (ENSG00000136866), ZNF614 (ENSG00000142556), KRBOX4 (ENSG00000147121), ZNF599 (ENSG00000153896), ZNF19 (ENSG00000157429), ZNF589 (ENSG00000164048), PRDM9 (ENSG00000164256), ZNF180 (ENSG00000167384), ZNF558 (ENSG00000167785), ZNF35 (ENSG00000169981), ZNF778 (ENSG00000170100), ZNF439 (ENSG00000171291), ZNF440 (ENSG00000171295), ZNF556 (ENSG00000172000), ZNF554 (ENSG00000172006), ZNF596 (ENSG00000172748), ZNF80 (ENSG00000174255), ZNF266 (ENSG00000174652), ZNF25 (ENSG00000175395), ZNF77 (ENSG00000175691), ZNF169 (ENSG00000175787), ZNF404 (ENSG00000176222), ZNF491 (ENSG00000177599), ZNF620 (ENSG00000177842), ZNF619 (ENSG00000177873), ZNF875 (ENSG00000181666), ZNF329 (ENSG00000181894), ZFP90 (ENSG00000184939), ZNF566 (ENSG00000186017), ZNF529 (ENSG00000186020), ZNF749 (ENSG00000186230), ZNF555 (ENSG00000186300)

Protein

Protein identifiers

Zinc finger protein 674 — Q2M3X9 (reviewed: Q2M3X9)

All UniProt accessions (3): Q2M3X9, A0A804HHU7, E5RHV3

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Tissue specificity. Expressed in testis.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q2M3X9-1	1	yes
Q2M3X9-2	2

RefSeq proteins (3): NP_001034980, NP_001139763, NP_001177346* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050752	C2H2-ZF_domain	Family

Pfam: PF00096, PF01352

UniProt features (20 total): zinc finger region 11, sequence variant 3, chain 1, domain 1, region of interest 1, compositionally biased region 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2M3X9-F1	65.55	0.18

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 52 (showing top): GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, chrXp11, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, PGF_UP.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ZIM3_TARGET_GENES, ZNF2_TARGET_GENES, ZNF30_TARGET_GENES, ZNF488_TARGET_GENES, ZNF766_TARGET_GENES, ZNF843_TARGET_GENES, MIR4728_5P, LET_7C_3P, MIR7106_5P, MIR10522_5P

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), developmental process (GO:0032502), negative regulation of DNA-templated transcription (GO:0045892), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872), sequence-specific double-stranded DNA binding (GO:1990837)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
DNA-templated transcription	2
transcription by RNA polymerase II	1
biological_process	1
negative regulation of RNA biosynthetic process	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription cis-regulatory region binding	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

574 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF674	ZNF385B	Q569K4	856
ZNF674	CHST7	Q9NS84	842
ZNF674	SLC9A7	Q96T83	698
ZNF674	TRIM28	Q13263	548
ZNF674	PHF8	Q9UPP1	530
ZNF674	NBPF1	Q3BBV0	513
ZNF674	NXF5	Q9H1B4	448
ZNF674	POGZ	Q7Z3K3	414
ZNF674	SHROOM4	Q9ULL8	400
ZNF674	ZCCHC12	Q6PEW1	380
ZNF674	PPP1R2C	O14990	367
ZNF674	ZBTB21	Q9ULJ3	354
ZNF674	TTK	P33981	350
ZNF674	NLGN4X	Q8N0W4	328
ZNF674	DUSP21	Q9H596	326

IntAct

4 interactions, top by confidence:

A	B	Type	Score
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ZNF674	H3-4	psi-mi:“MI:0915”(physical association)	0.400
ZNF674	SERPINA3	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): ZNF674 (Proximity Label-MS), S100A7 (Affinity Capture-MS), SBSN (Affinity Capture-MS), SERPINA3 (Affinity Capture-MS), S100A7A (Affinity Capture-MS), SERPINB4 (Affinity Capture-MS), ZNF674 (Affinity Capture-MS), ZNF674 (Affinity Capture-MS), ZNF674 (Affinity Capture-RNA)

ESM2 similar proteins: A0A087WUV0, A0JNB1, A2VDP4, B2RUI1, P0CG31, P10072, P17025, P17036, P17097, P18733, P51814, Q08ER8, Q09FC8, Q0VGE8, Q14590, Q15937, Q16600, Q2M3X9, Q4V8A8, Q5CZA5, Q5R8G9, Q5RBX0, Q5VIY5, Q68DI1, Q6J6I6, Q6NX49, Q6P1L6, Q6PG37, Q6ZMS4, Q6ZMW2, Q80YP6, Q86UD4, Q86Y25, Q8IZ26, Q8N184, Q8NB42, Q8NEK5, Q8TAF7, Q8TF47, Q8WXB4

Diamond homologs: A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587, Q2M3X9, Q2VY69, Q32M78, Q3ZCX4, Q49AA0, Q4R6J4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

97 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	59
Likely benign	9
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
625640	GRCh37/hg19 Xp11.3-11.23(chrX:43507300-48929622)	Pathogenic

SpliceAI

1720 predictions. Top by Δscore:

Variant	Effect	Δscore
X:46514560:T:TA	donor_gain	1.0000
X:46528742:A:AC	donor_gain	1.0000
X:46528743:C:CC	donor_gain	1.0000
X:46528822:C:A	donor_gain	1.0000
X:46542069:TCA:T	donor_loss	1.0000
X:46542070:CA:C	donor_loss	1.0000
X:46545369:A:AC	donor_gain	1.0000
X:46545370:C:CC	donor_gain	1.0000
X:46522953:CAGG:C	donor_gain	0.9900
X:46528821:T:TA	donor_gain	0.9900
X:46540443:CTT:C	donor_gain	0.9900
X:46540444:TTT:T	donor_gain	0.9900
X:46540445:TTT:T	donor_gain	0.9900
X:46542067:ACT:A	donor_loss	0.9900
X:46542071:A:AC	donor_gain	0.9900
X:46542072:C:CC	donor_gain	0.9900
X:46542117:C:CC	acceptor_gain	0.9900
X:46544494:AACT:A	donor_loss	0.9900
X:46544495:ACTCA:A	donor_loss	0.9900
X:46544496:CTCA:C	donor_loss	0.9900
X:46544497:TCA:T	donor_loss	0.9900
X:46544498:CA:C	donor_loss	0.9900
X:46544500:C:CA	donor_loss	0.9900
X:46544500:CCT:C	donor_gain	0.9900
X:46544791:T:TA	donor_gain	0.9900
X:46545370:CTT:C	donor_gain	0.9900
X:46545370:CTTCA:C	donor_gain	0.9900
X:46545372:T:TA	donor_gain	0.9900
X:46528444:CC:C	acceptor_gain	0.9800
X:46528445:CC:C	acceptor_gain	0.9800

AlphaMissense

3846 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:46499987:G:C	F534L	0.998
X:46499987:G:T	F534L	0.998
X:46499989:A:G	F534L	0.998
X:46499903:G:C	F562L	0.997
X:46499903:G:T	F562L	0.997
X:46499905:A:G	F562L	0.997
X:46500071:G:C	F506L	0.997
X:46500071:G:T	F506L	0.997
X:46500073:A:G	F506L	0.997
X:46500806:G:C	F261L	0.997
X:46500806:G:T	F261L	0.997
X:46500808:A:G	F261L	0.997
X:46500239:A:C	F450L	0.996
X:46500239:A:T	F450L	0.996
X:46500241:A:G	F450L	0.996
X:46500722:A:C	F289L	0.996
X:46500722:A:T	F289L	0.996
X:46500724:A:G	F289L	0.996
X:46499970:A:G	L540P	0.995
X:46500155:A:C	F478L	0.995
X:46500155:A:T	F478L	0.995
X:46500157:A:G	F478L	0.995
X:46500323:G:C	F422L	0.995
X:46500323:G:T	F422L	0.995
X:46500325:A:G	F422L	0.995
X:46500138:A:G	L484P	0.994
X:46500042:T:G	Q516P	0.993
X:46500126:T:G	Q488P	0.993
X:46500128:A:C	H487Q	0.993
X:46500128:A:T	H487Q	0.993

dbSNP variants (sampled 300 via entrez): RS1000143601 (X:46526543 G>A), RS1000190741 (X:46527816 GGTAGA>G), RS1000312589 (X:46498999 A>G), RS1000397923 (X:46513614 G>A,T), RS1000426257 (X:46510227 C>A,T), RS1000559602 (X:46524619 G>A), RS1000592851 (X:46519004 A>C), RS1000622363 (X:46510595 C>A), RS1000623997 (X:46518671 G>A,C), RS1000631070 (X:46528406 C>A), RS1000736448 (X:46511237 TATAAAG>T), RS1000742592 (X:46536418 T>C), RS1000789704 (X:46546225 G>A), RS1000905542 (X:46545746 C>T), RS1000922825 (X:46508572 G>A)

Disease associations

OMIM: gene MIM:300573 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability	Disputed Evidence	X-linked
X-linked intellectual disability	Disputed Evidence	X-linked

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
X-linked intellectual disability	Disputed	XL

Mondo (2): intellectual disability (MONDO:0001071), X-linked intellectual disability (MONDO:0100284)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	2
triphenyl phosphate	affects expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	increases abundance, increases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	increases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation, affects methylation	1
Calcitriol	decreases expression	1
Cisplatin	increases expression	1
Manganese	increases abundance, increases expression	1
Methapyrilene	decreases methylation	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	increases expression	1
Aflatoxin B1	affects methylation	1
Acrylamide	increases expression	1
Particulate Matter	increases expression, increases abundance	1

Clinical trials (associated diseases)

198 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders